Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events
Sign Up to like & getrecommendations! Published in 2025 at "American Journal of Hematology"
DOI: 10.1002/ajh.70015
Abstract: Belantamab mafodotin (belamaf)‐containing regimens are effective treatment options for patients with relapsed and/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be managed by physicians, following appropriate training,… read more here.
Keywords: practical guidance; ocular events; guidance clinical; belantamab mafodotin ... See more keywords
Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
Sign Up to like & getrecommendations! Published in 2022 at "Cornea"
DOI: 10.1097/ico.0000000000003162
Abstract: Supplemental Digital Content is Available in the Text. Abstract: Emerging monoclonal antibody therapies are assuming greater importance in the management of severe and refractory forms of immunity-driven and oncological disorders. However, some have been found… read more here.
Keywords: adverse ocular; belantamab mafodotin; etiology; management ... See more keywords
The incidence and characteristics of giant cell arteritis in Hispanics and the associated outcomes of ischemic ocular events and stroke
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Investigative Medicine"
DOI: 10.1177/10815589231152821
Abstract: Giant cell arteritis (GCA) is a large vessel vasculitis whereby up to half of all patients show ocular involvement, highlighting the importance of treating GCA before it leads to irreversible blindness. Most of the research… read more here.
Keywords: gca; events stroke; incidence; giant cell ... See more keywords